


<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/500,832	ATTY. DOCKET NO.: B0192.70051US00
				FILING DATE: January 1, 2005	CONFIRMATION NO.: 8927
				APPLICANT: Karlsen et al.	
				GROUP ART UNIT: 1637	EXAMINER: Christopher M. Babic
Sheet	1	of	2		



#### U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A2	5,506,105		Haydock	04-09-1996
	A3	5,654,416		Cummins et al.	08-05-1997
	A4	5,750,334		Cerutti et al.	05-12-1998
	A5	6,027,891		Von Knebel-Doberitz et al.	02-22-2000
	A6	2004-0214302	A1	Anthony et al.	10-28-2004
	A7	5,580,970		Hendricks et al.	12-03-1996
	A8	6,027,891		Wu	02-22-2000
	A9	2005-0118568		Karlsen	06-02-2005

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C15	In Re DEUEL 34 USPQ 2d 1210 (Fed. Cir. 1995)	
	C16	ANDERSON et al., Human papillomavirus and cervical cancer. Clin Microbiol Newslett. 2002 Aug 1;24(15):113.	
	C17	BOSCH et al., Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference. J Clin Pathol. 2001 Mar;54(3):163-75.	
	C18	BUCK et al. (1999) Design strategies and performance of custom DNA sequencing primers. Biotechniques. Vol. 27, pp. 528-536	
	C19	CLIFFORD et al., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003 Jan 13;88(1):63-73.	
	C20	CUSCHIERI et al., Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring. J Med Virol. 2004 May;73(1):65-70.	
	C21	DUENSING et al., Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 2004 Mar 20;109(2):157-62.	
	C22	JEON et al., Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol. 1995 May;69(5):2989-97.	
	C23	KARLSEN et al., Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol. 1996 Sep;34(9):2095-100.	
	C24	KIEVITS et al. (1991) NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. Journal of Virological Methods. Vol. 35, pp. 273-286	
	C25	KLAES et al., Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/500,832		ATTY. DOCKET NO.: B0192.70051US00	
				FILING DATE: January 1, 2005		CONFIRMATION NO.: 8927	
				APPLICANT: Karlsen et al.			
				GROUP ART UNIT: 1637		EXAMINER: Christopher M. Babic	
Sheet	2	of	2				

		amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999 Dec 15;59(24):6132-6.	
	C26	KRAUS et al., Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer. 2004 Apr 5;90(7):1407-13.	
	C27	KRAUS et al., Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006 Apr;44(4):1310-7.	
	C28	LIE et al., DNA versus RNA based methods for HPV testing in Norway. Evaluation of Hybrid Capture II and PreTect HPV-Proofer, a validation study. 21 <sup>st</sup> International Papillomavirus Conference, 20-26 February, Mexico City, Mexico.	
	C29	MOLDEN et al., Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72.	
	C30	MOLDEN et al., Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol Oncol. 2006 Jan;100(1):95-100. Epub 2005 Sep 8.	
	C31	MUNOZ et al., Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 Aug 20;111(2):278-85.	
	C32	PIM et al., Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene. 1997 Jul 17;15(3):257-64.	
	C33	SCHNEIDER-GADICKE et al., Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J. 1986 Sep;5(9):2285-92.	
	C34	SIMPKINS et al. (January 2000) An RNA transcription-based amplification technique (NASBA) for the detection of viable Salmonella enterica. Letters in Applied Microbiology. Vol. 30, pp. 75-79	
	C35	SOLTAR et al., Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol. 2004 Sep;74(1):107-16.	
	C36	TYAGI et al. (1996) Molecular Beacons: Probes that Fluoresce upon Hybridization. Nature Biotechnology. 14: 303-308	
	C37	VAN DEN BRULE et al., Difference in prevalence of human papillomavirus genotypes in cytologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer. 1991 May 30;48(3):404-8.	
	C38	YATES et al. (October 2001) Quantitative detection of Hepatitis B Virus DNA by real-time nucleic acid sequence-based amplification with molecular beacon detection. Journal of Clinical Microbiology. Vol. 39, pp. 3656-3665	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.